Druck Icon

Eckert & Ziegler and IBt to consolidate Implant Businesses

(Ad hoc press release)

Berlin, 28 February 2008 - Eckert & Ziegler and IBt have reached an agreement about the consolidation of their respective Businesses for Prostate Cancer Implants and executed a Share Contribution Agreement, in which Eckert & Ziegler sells its Implant Business to IBt with immediate effect in exchange for 6.75 million IBt shares. As a result, Eckert & Ziegler will become IBt's largest shareholder, owning about 40% of all rights to dividends and other economic benefits, and close to 30% of the voting rights in IBt's shareholder meeting. The difference in the two ratios is due to the existence of so-called Beneficiary Shares, which only convey voting rights in the shareholder meeting, but not to dividends. Eckert & Ziegler, as part of the transaction, also received an option to acquire all Beneficiary Shares. If Eckert & Ziegler exercised the option, it would control more than 52% of all IBt shares, and be obliged to provide a mandatory take-over bid.

"We do not intend to take control of IBt, and hence will leave the beneficiary shares at current with the founders of IBt, who initially designed them as a sort of poison pill against unfriendly takeovers", explains Andreas Eckert, CEO and founder of Eckert & Ziegler. "Our main focus now is primarily to make IBt-BEBIG the undisputed European leader for brachytherapy products, to develop the interesting product pipeline, and to benefit from the synergies in production and sales that the combination offers."

The combined entity will be run by a management team from both IBt and BEBIG, the latter one being represented by Edgar Löffler and Gunnar Mann, BEBIG's General Manager. François Blondel will be the CEO. As a consequence of the sale of the Implant Business, EZAG in 2008 expects a slightly lower absolute profitability than the 1 EUR per share initially communicated. The exact number will be provided once the integration team have had a chance to come with specific recommendations, but at the latest at the annual results press conference on 28 March 2008. Revenues in 2008 for the Group, however, will most likely surpass 70 million EUR.

"In terms of economic value traded, that is, in 2007 EBITDA numbers, Eckert & Ziegler will receive somewhat less than it brings into the consolidation", explains Andreas Eckert. "However we are sure that Eckert & Ziegler benefits more from having this deal than by going alone. For one thing, IBt has an interesting technology which will allow the introduction of a new greatly improved family of prostate implants. Then, the joint activities, with their very complementary sales and distribution network, will allow Eckert & Ziegler to grow the EBITDA quicker than it would be able to do on a standalone basis." IBt has already taken the necessary steps for an increased profitability, and the synergies that can be harvested seem quite substantial. Last not least, IBt will transfer a number of assets to EZAG in order to compensate for imbalances. Among these are two cyclotrons formerly used to produce Palladium, which, after being refitted, may allow Eckert & Ziegler to strengthen its radiopharmaceutical production activities. Together with some other assets the economic value to EZAG of these compensations results in more than 10 million EUR.

The Board of Directors